logo.jpg
Vallon Pharmaceuticals Reports Third Quarter 2022 Financial Results
November 03, 2022 16:30 ET | Vallon Pharmaceuticals Inc.
PHILADELPHIA, PA, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Vallon Pharmaceuticals, Inc. (NASDAQ: VLON), (“Vallon” or the “Company”), a clinical-stage biopharmaceutical company primarily focused on the...
logo.jpg
Vallon Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate Update
July 28, 2022 08:00 ET | Vallon Pharmaceuticals Inc.
PHILADELPHIA, PA, July 28, 2022 (GLOBE NEWSWIRE) -- Vallon Pharmaceuticals, Inc. (NASDAQ: VLON), (“Vallon” or the “Company”), a clinical-stage biopharmaceutical company primarily focused on the...
logo.jpg
Vallon Pharmaceuticals to Participate at the 5th Annual Neuroscience Innovation Forum
March 23, 2022 08:00 ET | Vallon Pharmaceuticals Inc.
David Baker, President and CEO of Vallon to participate in the virtual Advances in Neuropsychiatry Panel, today, March 23rd at 9:00 AM ET Philadelphia, PA, March 23, 2022 (GLOBE NEWSWIRE) --...
logo.jpg
Vallon Pharmaceuticals Announces Issuance of U.S. Patent Covering ADAIR for the Treatment of Cognitive Impairment Associated with COVID-19
February 28, 2022 08:05 ET | Vallon Pharmaceuticals Inc.
- Company in ongoing discussions with a major academic research center for design and execution of proof-of-concept study evaluating ADAIR for the treatment of cognitive impairment associated with...
logo.jpg
Vallon Pharmaceuticals to Present at the Virtual Investor 2022 Top Picks Conference
January 20, 2022 08:35 ET | Vallon Pharmaceuticals Inc.
– Live video webcast presentation on Tuesday, January 25th at 9:00 AM ET PHILADELPHIA, PA, Jan. 20, 2022 (GLOBE NEWSWIRE) -- Vallon Pharmaceuticals, Inc. (NASDAQ: VLON), (“Vallon” or the...
logo.jpg
Vallon Pharmaceuticals Announces Achievement of Last Patient Last Visit in Pivotal SEAL Study for Lead Program, ADAIR
December 23, 2021 08:05 ET | Vallon Pharmaceuticals Inc.
- Topline results from pivotal SEAL study expected in Q1 2022 - If approved, ADAIR will target the growing Adderall® segment of the ~$9 billion U.S. ADHD market PHILADELPHIA, PA, Dec. ...
logo.jpg
Vallon Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Corporate Update
November 12, 2021 08:05 ET | Vallon Pharmaceuticals Inc.
- Ongoing pivotal intranasal abuse study of lead program, ADAIR, advancing toward completion of patient enrollment and treatment in Q1 2022 - Advancement of second development program, ADMIR, with...
logo.jpg
Vallon Pharmaceuticals Presents Data from Adult Stimulant Abuse Pattern Survey at the American Academy of Child and Adolescent Psychiatry (AACAP) 68th Annual Meeting
November 01, 2021 08:35 ET | Vallon Pharmaceuticals Inc.
- Results suggest that developing stimulant formulations with abuse deterrent properties by non-oral routes may potentially reduce negative consequences of misuse, abuse, and diversion of stimulant...
logo.jpg
Vallon Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Corporate Update
August 10, 2021 08:05 ET | Vallon Pharmaceuticals Inc.
- Company continues to drive enrollment in pivotal intranasal abuse study evaluating ADAIR toward completion before year-end 2021 - ADAIR targeting the large and growing Adderall® segment of the...
logo.jpg
Vallon Pharmaceuticals Announces Issuance of New European Patent Covering Method of Use and Composition of Matter for ADAIR
July 13, 2021 08:05 ET | Vallon Pharmaceuticals Inc.
- Patent bolsters intellectual property protection as Company’s partner, MEDICE, works to develop and potentially commercialize ADAIR in Europe and the UK PHILADELPHIA, PA, July 13, 2021 (GLOBE...